HOME>CSR>Editorial Policies

Editorial Policies

This website is intended to provide the Group's stakeholders, including patients, medical professionals, shareholders, investors, local communities, and employees, with information about the CSR activities implemented by the Group in fiscal 2017. Specific initiatives implemented in accordance with the Company's philosophy are presented in line with the ISO 26000 Core Subjects. For the environmental and social performance indicators included in this report, we received third-party assurance from KPMG AZSA Sustainability Co., Ltd., from an independent viewpoint. Indicators for which assurance has been received are shown with the mark.

Explanations of medical and pharmaceutical terms appearing in this report have been provided to foster a wider understanding of the report's content.

Applied Guidelines

ISO26000;
Global Reporting Initiative (GRI) Sustainability Reporting Standard;
Environmental Reporting Guidelines, 2018 version, published by the Ministry of the Environment of Japan

Period covered

April 1, 2017, to March 31, 2018
(The report includes examples of activities from April 2018 and thereafter.)

Issue timing

September 2018 (Previous report: September 2017; next report: September 2019)

Scope of reporting

Mitsubishi Tanabe Pharma and consolidated subsidiaries in Japan and overseas.
(The scope of reporting could differ in accordance with the examples being reported.)

Contact information

Corporate Communications Department
u-g-f.info
3-2-10, Dosho-machi, Chuo-ku, Osaka City
Tel: +81-6-6205-5211
Fax: +81-6-6205-5105

Contact Us

CSR

CSR
Activities
Report
2018

CSR Activities Report 2018

PDF Download

Mitsubishi
Tanabe
Pharma
Corporate
Report
2018

Corporate Report 2018

PDF Download

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide